Amyotrophic Lateral Sclerosis (ALS) Market: Growth, Trends, and Forecast 2025 | Top key players - BIOGEN, Sanofi, Otsuka Holdings Co., Ltd.

The Global Amyotrophic Lateral Sclerosis (ALS) Market reached US$ 0.82 billion in 2024 and is expected to reach US$ 1.22 billion by 2033, growing at a CAGR of 5.1 % during the forecast period of 2025-2033.

Amyotrophic Lateral Sclerosis (ALS) Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic expansion, and capitalizing on new opportunities in today's rapidly evolving global landscape.

The Amyotrophic Lateral Sclerosis (ALS) Market includes the development, production, and distribution of treatments aimed at managing ALS, a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord. This market focuses on innovative therapies, diagnostic tools, and supportive care to improve patient quality of life and slow disease progression, driven by ongoing research and unmet medical needs.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/amyotrophic-lateral-sclerosis-market?sz

Amyotrophic Lateral Sclerosis (ALS) Market Recent Development:

In September 2024, Eisai Co., Ltd. received marketing authorization approval in Japan for Rozebalamin (Mecobalamin) to treat patients with amyotrophic lateral sclerosis (ALS). This approval provides a new therapeutic option aimed at addressing the neurodegenerative progression of ALS.

In August 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for tofersen (QALSODY), developed by Biogen Inc., for the treatment of ALS in adults with a mutation in the superoxide dismutase 1 (SOD1) gene. Available as a 100 mg/15 mL injection, QALSODY is the first FDA-approved therapy to target a genetic cause of ALS, marking a significant milestone in personalized neurology treatment.

List of the Key Players in the Amyotrophic Lateral Sclerosis (ALS) Market:

BIOGEN, Sanofi, Otsuka Holdings Co., Ltd., Mitsubishi Tanabe Pharma, EDW Pharma, Inc., BrainStorm Cell Therapeutics, Eisai Co., Ltd., Rappta Therapeutics, AB Science, and CorestemChemon Inc., among others.

Research Process:

Both primary and secondary data sources have been used in the global Amyotrophic Lateral Sclerosis (ALS) Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/amyotrophic-lateral-sclerosis-market

Segment Covered in the Amyotrophic Lateral Sclerosis (ALS) Market:

By Disease Type: Sporadic ALS, Familial ALS (FALS).

By Treatment Type: Riluzole, Edaravone, Sodium Phenylbutyrate and Taurursodiol, Tofersen, Dextromethorphan HBr and Quinidine Sulfate, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis for Amyotrophic Lateral Sclerosis (ALS) Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

People Also Ask:

Most Frequently Asked Questions in the Amyotrophic Lateral Sclerosis (ALS) Market Research Industry:

➠ What are the global figures for sales, production, consumption, imports, and exports in the Amyotrophic Lateral Sclerosis (ALS) market?

➠ Who are the top manufacturers in the global Amyotrophic Lateral Sclerosis (ALS) industry, and what is their current status in terms of production capacity, output, sales performance, pricing structure, cost analysis, profit margins, and overall revenue?

➠ What key opportunities are available for vendors in the Amyotrophic Lateral Sclerosis (ALS) market, and what challenges are they likely to encounter?

➠ Which application areas, end-user segments, or product types are projected to experience significant growth, and how is the market share distributed among them?

➠ What are the major drivers and barriers influencing the growth trajectory of the Amyotrophic Lateral Sclerosis (ALS) market?

➠ What are the primary sales, marketing, and distribution strategies used across the global Amyotrophic Lateral Sclerosis (ALS) industry landscape?

Browse More Reports: https://www.datamintelligence.com/research-report/amyotrophic-lateral-sclerosis-market

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.